CO2020006886A2 - Composición y método para tratar el linfoma periférico de linfocitos t y el linfoma cutáneo de linfocitos t - Google Patents

Composición y método para tratar el linfoma periférico de linfocitos t y el linfoma cutáneo de linfocitos t

Info

Publication number
CO2020006886A2
CO2020006886A2 CONC2020/0006886A CO2020006886A CO2020006886A2 CO 2020006886 A2 CO2020006886 A2 CO 2020006886A2 CO 2020006886 A CO2020006886 A CO 2020006886A CO 2020006886 A2 CO2020006886 A2 CO 2020006886A2
Authority
CO
Colombia
Prior art keywords
cell lymphoma
cutaneous
composition
treating peripheral
inhibitor
Prior art date
Application number
CONC2020/0006886A
Other languages
English (en)
Inventor
Swaroop Kumar Venkata Satya Vakkalanka
Original Assignee
Rhizen Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals Sa filed Critical Rhizen Pharmaceuticals Sa
Publication of CO2020006886A2 publication Critical patent/CO2020006886A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al uso de un inhibidor selectivo dual de proteína quinasa PI3K delta y gamma, tal como (S)-2-(1-((9H-purin-6-il)amino)propil)-3-(3-fluorofenil)-4H-cromen-4-ona (Compuesto (A), también conocido como tenalisib) o una sal aceptable desde el punto de vista farmacéutico de esta o una composición farmacéutica que contenga tal inhibidor para el tratamiento del linfoma periférico de linfocitos T (PTCL) y el linfoma cutáneo de linfocitos T (CTCL).
CONC2020/0006886A 2017-12-06 2020-06-03 Composición y método para tratar el linfoma periférico de linfocitos t y el linfoma cutáneo de linfocitos t CO2020006886A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741043740 2017-12-06
PCT/IB2018/059680 WO2019111185A1 (en) 2017-12-06 2018-12-05 Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma

Publications (1)

Publication Number Publication Date
CO2020006886A2 true CO2020006886A2 (es) 2020-08-31

Family

ID=65012059

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0006886A CO2020006886A2 (es) 2017-12-06 2020-06-03 Composición y método para tratar el linfoma periférico de linfocitos t y el linfoma cutáneo de linfocitos t

Country Status (15)

Country Link
US (1) US20200289520A1 (es)
EP (1) EP3720557A1 (es)
JP (1) JP2021505571A (es)
KR (1) KR20200096781A (es)
CN (1) CN111770776A (es)
AU (1) AU2018378415A1 (es)
BR (1) BR112020011167A2 (es)
CA (1) CA3084905A1 (es)
CL (1) CL2020001482A1 (es)
CO (1) CO2020006886A2 (es)
EA (1) EA202091082A1 (es)
IL (1) IL275028A (es)
MX (1) MX2020005771A (es)
SG (1) SG11202005208QA (es)
WO (1) WO2019111185A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014195888A1 (en) * 2013-06-07 2014-12-11 Rhizen Pharmaceuticals Sa Dual selective pi3 delta and gamma kinase inhibitors
EP4149629A1 (en) * 2020-05-14 2023-03-22 Rhizen Pharmaceuticals AG Purine derivatives as sik-3 inhibitors
CN117222413A (zh) * 2021-02-10 2023-12-12 同润生物医药(上海)有限公司 治疗肿瘤的方法和组合
KR20230045895A (ko) * 2021-09-29 2023-04-05 사회복지법인 삼성생명공익재단 말초 t세포 림프종 예후 예측용 신규 바이오마커 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0545913B1 (en) 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
SI1572744T1 (sl) 2002-12-16 2010-09-30 Genentech Inc Imunoglobulinske variante in njihove uporabe
CN105801550B (zh) * 2009-11-05 2019-06-14 理森制药股份公司 新型苯并吡喃激酶调节剂
WO2014195888A1 (en) * 2013-06-07 2014-12-11 Rhizen Pharmaceuticals Sa Dual selective pi3 delta and gamma kinase inhibitors

Also Published As

Publication number Publication date
WO2019111185A1 (en) 2019-06-13
EP3720557A1 (en) 2020-10-14
CL2020001482A1 (es) 2020-11-20
US20200289520A1 (en) 2020-09-17
IL275028A (en) 2020-07-30
MX2020005771A (es) 2020-10-28
SG11202005208QA (en) 2020-07-29
CN111770776A (zh) 2020-10-13
CA3084905A1 (en) 2019-06-13
BR112020011167A2 (pt) 2020-11-17
EA202091082A1 (ru) 2020-10-23
AU2018378415A1 (en) 2020-07-23
KR20200096781A (ko) 2020-08-13
JP2021505571A (ja) 2021-02-18

Similar Documents

Publication Publication Date Title
CO2020006886A2 (es) Composición y método para tratar el linfoma periférico de linfocitos t y el linfoma cutáneo de linfocitos t
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
MX2020014245A (es) Inhibidores de quinasas dependientes de ciclinas.
BR112018071585A2 (pt) formulações de um inibidor de lsd1
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
EA201692285A8 (ru) Ингибиторы ezh2 для лечения лимфомы
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
MX2019002962A (es) Inhibidores espirobiciclicos de la interaccion de menina-mll.
BR112015030515A2 (pt) intensificadores de inibidores de homólogo 2 de zeste
AR112103A1 (es) Compuestos para el tratamiento de tnbc
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
BR112022008365A2 (pt) Inibidores de cd73
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
MX2020006594A (es) Inhibidores de exo-azaespiro de la interaccion menina-mll.
BR112017023855A2 (pt) o uso de estimulantes de sgc, ativadores de scg, em separado e combinações com inibidores de pde5 para o tratamento de úlceras digitais (du) concomitantes à esclerose múltipla (ssc)
CO2019009000A2 (es) Combinaciones farmacéuticas para tratar cáncer
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
AR100289A1 (es) Formas de un inhibidor de pi3k
CL2008003062A1 (es) Compuestos derivados de pirazoles espiro conjugados, inhibidores de la actividad de ksp kinesina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.